Benjamin Palleiko Sells 6,693 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 6,693 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $16.08, for a total value of $107,623.44. Following the sale, the chief executive officer owned 451,815 shares in the company, valued at approximately $7,265,185.20. The trade was a 1.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

KalVista Pharmaceuticals Stock Down 1.1%

NASDAQ KALV opened at $18.24 on Thursday. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The business has a 50 day moving average price of $15.70 and a two-hundred day moving average price of $14.22. The stock has a market cap of $922.03 million, a PE ratio of -4.62 and a beta of -0.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on KALV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Needham & Company LLC lifted their price objective on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $55,000. Wolverine Asset Management LLC bought a new position in KalVista Pharmaceuticals during the 3rd quarter worth $57,000. KLP Kapitalforvaltning AS acquired a new stake in KalVista Pharmaceuticals in the third quarter worth $63,000. Finally, Truvestments Capital LLC lifted its stake in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 3,360 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.